Full Dose Neoadjuvant FOLFIRINOX is Associated with Prolonged Survival in Patients with Locally Advanced Pancreatic Adenocarcinoma

Moh'D Khushman; Naomi Dempsey; Jennifer Cudris Maldonado; Arturo Loaiza-Bonilla; Michel Velez; Lauren Carcas; Daniel Dammrich; Jorge Hurtado-Cordovi; Ritesh Parajuli; Terri Pollack; Ana P. Harwood; Jessica Macintyre; Ching-Wei David Tzeng; Jaime R. Merchan; Maria H. Restrepo; Ikechukwu I. Akunyili; Afonso Ribeiro; Govindarajan Narayanan; Lorraine Portelance; Danny Sleeman; Joe U. Levi; Caio M.S. Rocha Lima; Peter J. Hosein

doi:10.1016/j.pan.2015.08.010

Full Dose Neoadjuvant FOLFIRINOX is Associated with Prolonged Survival in Patients with Locally Advanced Pancreatic Adenocarcinoma

Moh'D Khushman, Naomi Dempsey, Jennifer Cudris Maldonado, Arturo Loaiza-Bonilla, Michel Velez, Lauren Carcas, Daniel Dammrich, Jorge Hurtado-Cordovi, Ritesh Parajuli, Terri Pollack, Ana P. Harwood, Jessica Macintyre, Ching-Wei David Tzeng, Jaime R. Merchan, Maria H. Restrepo, Ikechukwu I. Akunyili, Afonso Ribeiro, Govindarajan Narayanan, Lorraine Portelance, Danny SleemanJoe U. Levi, Caio M.S. Rocha Lima, Peter J. Hosein

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Pancreatology
Volume	15
DOIs	https://doi.org/10.1016/j.pan.2015.08.010
State	Published - Nov 1 2015

Disciplines

Oncology
Internal Medicine
Medicine and Health Sciences
Surgery

Access to Document

10.1016/j.pan.2015.08.010License: Unspecified

Cite this

Khushman, MD., Dempsey, N., Maldonado, J. C., Loaiza-Bonilla, A., Velez, M., Carcas, L., Dammrich, D., Hurtado-Cordovi, J., Parajuli, R., Pollack, T., Harwood, A. P., Macintyre, J., Tzeng, C.-W. D., Merchan, J. R., Restrepo, M. H., Akunyili, I. I., Ribeiro, A., Narayanan, G., Portelance, L., ... Hosein, P. J. (2015). Full Dose Neoadjuvant FOLFIRINOX is Associated with Prolonged Survival in Patients with Locally Advanced Pancreatic Adenocarcinoma. Pancreatology, 15. https://doi.org/10.1016/j.pan.2015.08.010

Khushman, MD, Dempsey, N, Maldonado, JC, Loaiza-Bonilla, A, Velez, M, Carcas, L, Dammrich, D, Hurtado-Cordovi, J, Parajuli, R, Pollack, T, Harwood, AP, Macintyre, J, Tzeng, C-WD, Merchan, JR, Restrepo, MH, Akunyili, II, Ribeiro, A, Narayanan, G, Portelance, L, Sleeman, D, Levi, JU, Lima, CMSR & Hosein, PJ 2015, 'Full Dose Neoadjuvant FOLFIRINOX is Associated with Prolonged Survival in Patients with Locally Advanced Pancreatic Adenocarcinoma', Pancreatology, vol. 15. https://doi.org/10.1016/j.pan.2015.08.010

@article{11567523ef544db8b73ddd28bb6d64c0,

title = "Full Dose Neoadjuvant FOLFIRINOX is Associated with Prolonged Survival in Patients with Locally Advanced Pancreatic Adenocarcinoma",

author = "Moh'D Khushman and Naomi Dempsey and Maldonado, {Jennifer Cudris} and Arturo Loaiza-Bonilla and Michel Velez and Lauren Carcas and Daniel Dammrich and Jorge Hurtado-Cordovi and Ritesh Parajuli and Terri Pollack and Harwood, {Ana P.} and Jessica Macintyre and Tzeng, {Ching-Wei David} and Merchan, {Jaime R.} and Restrepo, {Maria H.} and Akunyili, {Ikechukwu I.} and Afonso Ribeiro and Govindarajan Narayanan and Lorraine Portelance and Danny Sleeman and Levi, {Joe U.} and Lima, {Caio M.S. Rocha} and Hosein, {Peter J.}",

note = "FOLFIRINOX is feasible as neoadjuvant therapy for LAPC. Although the R0 resection rate was only 20%, the median OS of almost 3 years appears promising. Dose intensity and duration were associated with increased survival in this study, arguing against dose attenuated versions of this regimen.",

year = "2015",

month = nov,

day = "1",

doi = "10.1016/j.pan.2015.08.010",

language = "American English",

volume = "15",

journal = "Pancreatology",

}

TY - JOUR

T1 - Full Dose Neoadjuvant FOLFIRINOX is Associated with Prolonged Survival in Patients with Locally Advanced Pancreatic Adenocarcinoma

AU - Khushman, Moh'D

AU - Dempsey, Naomi

AU - Maldonado, Jennifer Cudris

AU - Loaiza-Bonilla, Arturo

AU - Velez, Michel

AU - Carcas, Lauren

AU - Dammrich, Daniel

AU - Hurtado-Cordovi, Jorge

AU - Parajuli, Ritesh

AU - Pollack, Terri

AU - Harwood, Ana P.

AU - Macintyre, Jessica

AU - Tzeng, Ching-Wei David

AU - Merchan, Jaime R.

AU - Restrepo, Maria H.

AU - Akunyili, Ikechukwu I.

AU - Ribeiro, Afonso

AU - Narayanan, Govindarajan

AU - Portelance, Lorraine

AU - Sleeman, Danny

AU - Levi, Joe U.

AU - Lima, Caio M.S. Rocha

AU - Hosein, Peter J.

N1 - FOLFIRINOX is feasible as neoadjuvant therapy for LAPC. Although the R0 resection rate was only 20%, the median OS of almost 3 years appears promising. Dose intensity and duration were associated with increased survival in this study, arguing against dose attenuated versions of this regimen.

PY - 2015/11/1

Y1 - 2015/11/1

UR - https://pubmed.ncbi.nlm.nih.gov/26412296/

U2 - 10.1016/j.pan.2015.08.010

DO - 10.1016/j.pan.2015.08.010

M3 - Article

VL - 15

JO - Pancreatology

JF - Pancreatology

ER -

Full Dose Neoadjuvant FOLFIRINOX is Associated with Prolonged Survival in Patients with Locally Advanced Pancreatic Adenocarcinoma

Disciplines

Access to Document

Other files and links

Cite this